TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of “Moderate Buy” by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $50.25.

A number of brokerages recently weighed in on TGTX. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Tuesday, November 25th. HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Signature Wealth Management Partners LLC raised its position in TG Therapeutics by 3.7% during the third quarter. Signature Wealth Management Partners LLC now owns 11,180 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 400 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of TG Therapeutics by 1.0% in the second quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company’s stock valued at $1,447,000 after purchasing an additional 417 shares during the last quarter. Amalgamated Bank increased its stake in shares of TG Therapeutics by 1.1% during the 3rd quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,418,000 after purchasing an additional 424 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of TG Therapeutics by 1.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after purchasing an additional 441 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in TG Therapeutics by 21.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 467 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TGTX opened at $33.19 on Monday. The stock’s 50-day moving average price is $33.87 and its 200 day moving average price is $33.91. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $46.48. The firm has a market cap of $5.27 billion, a price-to-earnings ratio of 89.69 and a beta of 1.95. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. The company had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business’s revenue for the quarter was up 92.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that TG Therapeutics will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.